SG159390A1 - Use of n-desmethyclozapine to treat human neuropsychiatric disease - Google Patents

Use of n-desmethyclozapine to treat human neuropsychiatric disease

Info

Publication number
SG159390A1
SG159390A1 SG200705214-5A SG2007052145A SG159390A1 SG 159390 A1 SG159390 A1 SG 159390A1 SG 2007052145 A SG2007052145 A SG 2007052145A SG 159390 A1 SG159390 A1 SG 159390A1
Authority
SG
Singapore
Prior art keywords
desmethyclozapine
neuropsychiatric disease
treat human
human neuropsychiatric
disease
Prior art date
Application number
SG200705214-5A
Other languages
English (en)
Inventor
David Weiner
Mark Brann
Original Assignee
Acadia Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acadia Pharm Inc filed Critical Acadia Pharm Inc
Publication of SG159390A1 publication Critical patent/SG159390A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG200705214-5A 2003-01-23 2004-01-21 Use of n-desmethyclozapine to treat human neuropsychiatric disease SG159390A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US44269003P 2003-01-23 2003-01-23

Publications (1)

Publication Number Publication Date
SG159390A1 true SG159390A1 (en) 2010-03-30

Family

ID=32772052

Family Applications (1)

Application Number Title Priority Date Filing Date
SG200705214-5A SG159390A1 (en) 2003-01-23 2004-01-21 Use of n-desmethyclozapine to treat human neuropsychiatric disease

Country Status (14)

Country Link
US (2) US20040224942A1 (ru)
EP (2) EP1589974A2 (ru)
JP (1) JP2006515628A (ru)
KR (1) KR20050092123A (ru)
CN (1) CN1741803A (ru)
AU (1) AU2004206931A1 (ru)
BR (1) BRPI0406592A (ru)
CA (1) CA2512043A1 (ru)
MX (1) MXPA05007784A (ru)
NZ (1) NZ541014A (ru)
RU (2) RU2336879C2 (ru)
SG (1) SG159390A1 (ru)
WO (1) WO2004064753A2 (ru)
ZA (1) ZA200505878B (ru)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001066521A1 (en) 2000-03-06 2001-09-13 Acadia Pharmaceuticals, Inc. Azacyclic compounds for use in the treatment of serotonin related diseases
WO2003057698A2 (en) 2001-12-28 2003-07-17 Acadia Pharmaceuticals, Inc. Spiroazacyclic compounds as monoamine receptor modulators
IL165907A0 (en) 2002-06-24 2006-01-15 Acadia Pharm Inc N-substituted piperidine derivatives as serotonin receptor agents
US7253186B2 (en) 2002-06-24 2007-08-07 Carl-Magnus Andersson N-substituted piperidine derivatives as serotonin receptor agents
US7538222B2 (en) 2002-06-24 2009-05-26 Acadia Pharmaceuticals, Inc. N-substituted piperidine derivatives as serotonin receptor agents
PT1587789E (pt) 2003-01-16 2008-12-16 Acadia Pharm Inc Agonistas inversos selectivos para receptores 2a/2c da serotonina como agentes terapêuticos para doenças neurodegenerativas
NZ541014A (en) * 2003-01-23 2008-05-30 Acadia Pharm Inc Use of N-desmethylclozapine to treat schizophrenia while increasing the level of activity of a muscarinic receptor
WO2006017614A1 (en) * 2004-08-05 2006-02-16 Acadia Pharmaceuticals Inc. Use of n-desmethylclozapine to treat human neuropsychiatric disease
US20050085463A1 (en) * 2003-01-23 2005-04-21 Weiner David M. Use of N-desmethylclozapine to treat human neuropsychiatric disease
US20050250767A1 (en) * 2003-01-23 2005-11-10 Weiner David M Use of N-desmethylclozapine to treat human neuropsychiatric disease
EP1596867A4 (en) * 2003-02-19 2006-03-22 Merck & Co Inc TREATMENT OF PSYCHOSIS WITH ECTOPIC ACTIVATOR OF M1 MUSCARINIC RECEPTOR
US20090093461A1 (en) * 2003-07-02 2009-04-09 Astrazeneca Ab Methods of Treating Anxiety and Mood Disorders
US20090093460A1 (en) * 2003-07-02 2009-04-09 Astrazeneca Ab Compositions
US20060252743A1 (en) * 2005-01-07 2006-11-09 Astrazeneca Ab Method of treating sleep disorders
US20070117789A1 (en) * 2005-11-18 2007-05-24 Astrazeneca Ab Method of treatment
US20060217367A1 (en) * 2004-07-01 2006-09-28 Astrazeneca Ab Method of treating anxiety disorders
US20060229292A1 (en) * 2005-01-07 2006-10-12 Astrazeneca Ab Method of treating childhood disorders
US20060217366A1 (en) * 2003-07-02 2006-09-28 Astrazeneca Ab Method of treating schizophrenia and other disorders
KR20060082037A (ko) * 2003-07-02 2006-07-14 아스트라제네카 아베 퀘티아핀의 대사산물
US20060217365A1 (en) * 2003-07-02 2006-09-28 Astrazeneca Ab Method of treating mood disorders
US20090239840A1 (en) * 2003-12-22 2009-09-24 Acadia Pharmaceuticals, Inc. AMINO SUBSTITUTED DIARYL[a,d]CYCLOHEPTENE ANALOGS AS MUSCARINIC AGONISTS AND METHODS OF TREATMENT OF NEUROPSYCHIATRIC DISORDERS
DE602004020263D1 (de) * 2003-12-22 2009-05-07 Acadia Pharm Inc Amino-substituierte diaryläa,dücyclohepten- analoga als muscarinische agonisten und verfahren zur behandlung von neuropsychiatrischen erkrankungen
US20050171088A1 (en) * 2004-01-30 2005-08-04 Astrazeneca Ab Treatment of psychoses with dibenzothiazepine antipsychotic
MXPA06011320A (es) * 2004-04-01 2007-03-21 Acadia Pharm Inc Metodo de sintesis y aislamiento de n-desmetilclozapina solida y sus formas cristalinas.
US20050261278A1 (en) * 2004-05-21 2005-11-24 Weiner David M Selective serotonin receptor inverse agonists as therapeutics for disease
US7820695B2 (en) 2004-05-21 2010-10-26 Acadia Pharmaceuticals, Inc. Selective serotonin receptor inverse agonists as therapeutics for disease
US7790899B2 (en) 2004-09-27 2010-09-07 Acadia Pharmaceuticals, Inc. Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms
CN101035759B (zh) 2004-09-27 2011-06-15 阿卡蒂亚药品公司 N-(4-氟苄基)-n-(1-甲基哌啶-4-基)-n’-(4-(2-甲基丙氧基)苯基甲基)脲及其酒石酸盐的合成和晶形
CA2599922A1 (en) * 2005-04-04 2006-10-12 Acadia Pharmaceuticals Inc. Use of n-desmethylclozapine and related compounds as dopamine stabilizing agents
WO2007025177A2 (en) * 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
WO2007053618A1 (en) * 2005-10-31 2007-05-10 Acadia Pharmaceuticals Inc. Prodrugs of muscarinic agonists and methods of treatment of neuropsychiatric disorders
US9221779B2 (en) 2006-06-22 2015-12-29 Ramot At Tel-Aviv University Ltd. Serotonin reuptake inhibitors as drugs having peripheral-system-restricted activity
US9278947B2 (en) 2006-06-22 2016-03-08 Ramot At Tel-Aviv University Ltd. Serotonin reuptake inhibitors as drugs having peripheral-system-restricted activity
ES2423485T3 (es) 2007-03-19 2013-09-20 Acadia Pharmaceuticals Inc. Asociaciones de agonistas y antagonistas inversos 5-HT2A con antipsicóticos
CA2728675A1 (en) 2008-06-20 2009-12-23 Astrazeneca Ab Dibenzothiazepine derivatives and use thereof
US9018202B2 (en) * 2010-12-03 2015-04-28 Allergan, Inc. Methods for treating diseases of the retina
RU2506073C1 (ru) * 2012-09-06 2014-02-10 Алексей Николаевич Паршин Способ лечения расстройства адаптации у пациентов с суицидальным риском
US20160184290A1 (en) * 2014-12-31 2016-06-30 Paul J. Markovitz Method of treating schizophrenia
SI3325444T1 (sl) 2015-07-20 2021-11-30 Acadia Pharmaceuticals Inc. Postopki za pripravo N-(4-fluorobenzil)-N-(1-metilpiperidin-4-il)-N'- (4-(2-metilpropiloksi)fenilmetil)karbamida in njegove tartratne soli in polimorfne oblike C
WO2017117347A1 (en) * 2015-12-30 2017-07-06 Markovitz M D Paul Method of treating schizophrenia
RU2667954C2 (ru) * 2016-03-04 2018-09-25 Общество С Ограниченной Ответственностью "Валентек" Фармацевтическая композиция для лечения функциональных психических расстройств
WO2017165635A1 (en) 2016-03-25 2017-09-28 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome p450 modulators
US10953000B2 (en) 2016-03-25 2021-03-23 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome P450 modulators
EP3558311A1 (en) 2016-12-20 2019-10-30 Acadia Pharmaceuticals Inc. Pimavanserin alone or in combination for use in the treatment of alzheimer's disease psychosis
US11135211B2 (en) 2017-04-28 2021-10-05 Acadia Pharmaceuticals Inc. Pimavanserin for treating impulse control disorder
US20210077479A1 (en) 2017-08-30 2021-03-18 Acadia Pharmaceuticals Inc. Formulations of pimavanserin
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
CN107970243B (zh) * 2017-10-30 2020-07-28 江苏理工学院 一种去甲氯氮平的新用途
CN109761826B (zh) * 2019-01-17 2022-02-25 烟台大学 一种o-去甲基文拉法辛苯醚化合物及其制备方法和用途
CN114206349A (zh) 2019-04-17 2022-03-18 指南针探路者有限公司 治疗神经认知障碍、慢性疼痛及减轻炎症的方法

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL140242B (nl) * 1963-03-01 1973-11-15 Wander Ag Dr A Werkwijze voor het bereiden van op de 11-plaats door een basische groep gesubstitueerde dibenz (b.f.)(1.4) oxazepinen.
US3389139A (en) * 1963-06-14 1968-06-18 Wander Ag Dr A 6-homopiperazino and piperazinomorphanthridines
US3908010A (en) * 1967-03-22 1975-09-23 Wander Ag Dr A Basically substituted heterocycles as anti-emetics
US3884920A (en) * 1967-07-14 1975-05-20 Sandoz Ag 11-Basically substituted dibenz {8 b,f{9 {0 {8 1,4{9 {0 oxazepines
US3412193A (en) * 1965-12-13 1968-11-19 American Cyanamid Co 11-(4-methyl-1-piperazinyl)dibenz[b, f][1, 4]oxazepines or thiazepines for controlling fertility
US3444169A (en) * 1966-01-17 1969-05-13 American Cyanamid Co Process for 11 - aminodibenz(b,f)(1,4)oxazepines and analogous thiazepines
GB1184251A (en) * 1966-04-15 1970-03-11 American Cyanamid Co Oxazepines and Thiazepines
GB1192812A (en) * 1966-05-20 1970-05-20 American Cyanamid Co 2-Chloro-11-(1-Piperazinyl)Dibenz[b,f]-[1,4]Oxazepine, Non-Toxic Acid Addition Salts thereof, and Therapeutic Compositions containing said Oxazepine or Salts
US3852446A (en) * 1967-03-13 1974-12-03 Sandoz Ag Organic compounds in treatment of psychotic disturbances
US3751415A (en) * 1967-03-22 1973-08-07 Sandoz Ag 2-nitro-11-(1-piperazinyl)-dibenz(b,f)(1,4)oxazepines
US3539573A (en) * 1967-03-22 1970-11-10 Jean Schmutz 11-basic substituted dibenzodiazepines and dibenzothiazepines
US3758479A (en) * 1967-03-22 1973-09-11 Sandoz Ag Nitro and sulphamoyl substituted dibenzodiazepines
CA918659A (en) * 1969-07-31 1973-01-09 Yoshitomi Pharmaceutical Industries 11-(4-substituted-1-piperazinyl)-dibenzo (b,f) (1,4) thiazepines
US3660406A (en) * 1970-10-26 1972-05-02 American Cyanamid Co 2-chloro-7-hydroxy-11-(1-piperazinyl)dibenz(b f)(1 4)oxazepines
CH555856A (de) * 1971-05-04 1974-11-15 Hoffmann La Roche Verfahren zur herstellung von tricyclischen verbindungen.
US3962248A (en) * 1972-04-04 1976-06-08 Sandoz, Inc. Process for making 11-piperazino-diazepines, oxazepines, thiazepines and azepines
US3884446A (en) * 1973-12-10 1975-05-20 Dahl Co G W Low profile control valve actuator
US3983234A (en) * 1974-07-04 1976-09-28 Sandoz Ltd. Treatment of dyskinesias
US4045445A (en) * 1975-12-14 1977-08-30 American Cyanamid Company 11-(4-Piperidyl)dibenzo-diazepines
CH624682A5 (ru) * 1976-11-10 1981-08-14 Sandoz Ag
US4406900A (en) * 1976-11-10 1983-09-27 Sandoz Ltd. Neuroleptic use of morphanthridines
US4096261A (en) * 1977-02-23 1978-06-20 Abbott Laboratories Dibenzodiazepines
US4097597A (en) * 1977-02-23 1978-06-27 Abbott Laboratories Dibenzo b,e! 1,4!diazepines
US4191760A (en) * 1977-02-23 1980-03-04 Abbott Laboratories Dibenzodiazepines
CS196893B1 (en) * 1977-12-22 1980-04-30 Miroslav Protiva 3-fluor-10-piperazino-8-substituted 10,11-dihydro-dibenzothiepines
US4263207A (en) * 1978-08-01 1981-04-21 Merck & Co., Inc. 10,11-Dihydrodibenzo[b,f][1,4]thiazepine carboxylic acids esters and amides thereof
US4268207A (en) * 1979-07-06 1981-05-19 Eaton Corporation Load support and shuttle
US4404137A (en) * 1979-10-16 1983-09-13 Lilly Industries Limited Pyrazolo [3,4-b][1,5]benzodiazepine compounds
CH641876A5 (de) * 1980-02-14 1984-03-15 Sulzer Ag Kolbenkompressor, insbesondere zum verdichten von sauerstoff.
US4663453A (en) * 1983-05-18 1987-05-05 Hoechst-Roussel Pharmaceuticals Inc. Benzo[b]pyrrolo[3,2,1-jk][1,4]benzodiazepines having dopamine receptor activity
US4764616A (en) * 1983-05-18 1988-08-16 Hoechst-Roussel Pharmaceuticals Inc. Benzopyrrolobenzodiazepines and quinobenzodiazepines
JPH04211071A (ja) * 1990-03-05 1992-08-03 Hokuriku Seiyaku Co Ltd 多環式化合物
US5817655A (en) * 1991-04-23 1998-10-06 Eli Lilly And Company Methods of treatment using a thieno-benzodiazepine
US5300422A (en) * 1991-12-04 1994-04-05 Case Western Reserve University Screening method for controlling agranulocytosis
US5393752A (en) * 1992-05-26 1995-02-28 Therabel Research S.A./N.V. Methylpiperazinoazepine compounds, preparation and use thereof
WO1994026107A1 (en) * 1993-05-13 1994-11-24 New York University Psychosis protecting nucleic acid, peptides, compositions and method of use
US5354747A (en) * 1993-06-16 1994-10-11 G. D. Searle & Co. 2-, 3-, 4-, 5-, 6-, 7-, 8-, 9- and/or 10-substituted dibenzoxazepine and dibenzthiazepine compounds, pharmaceutical compositions and methods of use
IL110298A (en) * 1993-07-13 1999-04-11 Brann Mark Robert Identification of ligands by selective amplification of cells transfected with receptors
US5538965A (en) * 1993-12-23 1996-07-23 Allelix Biopharmaceuticals Inc. Dopamine receptor ligands
US6566065B1 (en) * 1994-05-26 2003-05-20 Mcgill University Method of diagnosing schizophrenia by detecting a mutation in the (MTHFR) gene
US5700445A (en) * 1994-12-12 1997-12-23 Allelix Biopharmaceuticals, Inc. N-methyl piperazine compounds having dopamine receptor affinity
US5602120A (en) * 1994-12-12 1997-02-11 Allelix Biopharmaceuticals, Inc. Benzyl-substituted compounds having dopamine receptor affinity
US5602124A (en) * 1994-12-12 1997-02-11 Allelix Biopharmaceuticals, Inc. 5-HT2 receptor ligands
US5602121A (en) * 1994-12-12 1997-02-11 Allelix Biopharmaceuticals, Inc. Alkyl-substituted compounds having dopamine receptor affinity
GB9617305D0 (en) * 1996-08-17 1996-09-25 Glaxo Wellcome Spa Heterocyclic compounds
ES2238437T3 (es) * 2000-04-28 2005-09-01 Acadia Pharmaceuticals Inc. Agonistas muscarinicos.
US6630462B2 (en) * 2000-11-17 2003-10-07 Adolor Corporation Delta agonist analgesics
AU2003272362A1 (en) * 2002-09-18 2004-04-08 Bayer Cropscience Ag Insecticidal tricyclic derivatives
EP1578198A1 (en) * 2002-12-20 2005-09-28 Basf Aktiengesellschaft Pesticidal dibenzo(hetero)azepine derivatives
PT1587789E (pt) * 2003-01-16 2008-12-16 Acadia Pharm Inc Agonistas inversos selectivos para receptores 2a/2c da serotonina como agentes terapêuticos para doenças neurodegenerativas
US20050085463A1 (en) * 2003-01-23 2005-04-21 Weiner David M. Use of N-desmethylclozapine to treat human neuropsychiatric disease
US20050250767A1 (en) * 2003-01-23 2005-11-10 Weiner David M Use of N-desmethylclozapine to treat human neuropsychiatric disease
NZ541014A (en) * 2003-01-23 2008-05-30 Acadia Pharm Inc Use of N-desmethylclozapine to treat schizophrenia while increasing the level of activity of a muscarinic receptor
US20070275957A1 (en) * 2003-01-23 2007-11-29 Weiner David M Use of n-desmethylclozapine to treat human neuropsychiatric disease
EP1596867A4 (en) * 2003-02-19 2006-03-22 Merck & Co Inc TREATMENT OF PSYCHOSIS WITH ECTOPIC ACTIVATOR OF M1 MUSCARINIC RECEPTOR
DE602004020263D1 (de) * 2003-12-22 2009-05-07 Acadia Pharm Inc Amino-substituierte diaryläa,dücyclohepten- analoga als muscarinische agonisten und verfahren zur behandlung von neuropsychiatrischen erkrankungen
MXPA06011320A (es) * 2004-04-01 2007-03-21 Acadia Pharm Inc Metodo de sintesis y aislamiento de n-desmetilclozapina solida y sus formas cristalinas.
EA012610B1 (ru) * 2004-09-21 2009-10-30 Хипнион, Инк. Аналоги локсапина и фармацевтические композиции на их основе
US20060063754A1 (en) * 2004-09-21 2006-03-23 Edgar Dale M Methods of treating a sleep disorder
CA2599922A1 (en) * 2005-04-04 2006-10-12 Acadia Pharmaceuticals Inc. Use of n-desmethylclozapine and related compounds as dopamine stabilizing agents
WO2007053618A1 (en) * 2005-10-31 2007-05-10 Acadia Pharmaceuticals Inc. Prodrugs of muscarinic agonists and methods of treatment of neuropsychiatric disorders

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DOES THE PHARMACOLOGICALLY ACTIVE N- DEMETHYLATED METABOLITE OF CLOZAPINE PASS THE BLOOD-BRAIN BARRIER? *
EFFECTS OF DESMETHYLCLOZAPINE ON FOS PROTEIN EXPRESSION IN THE FOREBRIAN: IN VIVO BIOLOGICAL ACTIVITY OF THE clozapine metabolite *

Also Published As

Publication number Publication date
EP1994932A1 (en) 2008-11-26
CA2512043A1 (en) 2004-08-05
MXPA05007784A (es) 2005-09-30
US20090018119A1 (en) 2009-01-15
RU2336879C2 (ru) 2008-10-27
US20040224942A1 (en) 2004-11-11
RU2005126614A (ru) 2006-01-27
ZA200505878B (en) 2006-04-26
WO2004064753A2 (en) 2004-08-05
EP1589974A2 (en) 2005-11-02
AU2004206931A1 (en) 2004-08-05
WO2004064753A3 (en) 2004-11-25
CN1741803A (zh) 2006-03-01
KR20050092123A (ko) 2005-09-20
BRPI0406592A (pt) 2005-12-20
JP2006515628A (ja) 2006-06-01
NZ541014A (en) 2008-05-30
RU2008116931A (ru) 2009-11-10

Similar Documents

Publication Publication Date Title
SG159390A1 (en) Use of n-desmethyclozapine to treat human neuropsychiatric disease
Wassermann et al. Use and safety of a new repetitive transcranial magnetic stimulator
MXPA04004552A (es) Compuestos tipo indolizina sustituida y metodos de uso.
IL151164A0 (en) Azacyclic compounds for use in the treatment of serotonin related diseases
IL172853A0 (en) Use of the quinazoline derivative zd6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability
HK1092358A1 (en) Method for producing medicaments for reducing amyloid deposition, amyloid neurotoxicity and microgloisis
ATE390928T1 (de) Zusammensetzungen zur behandlung von hauterkrankungen
MX2021015498A (es) Derivados de imidazo[1,2-a]piridinilo y su uso en el tratamiento de enfermedades.
MX2021015499A (es) Derivados de 2h-indazol y su uso en el tratamiento de enfermedades.
SE0400184D0 (sv) New therapeutical use
MX2008013635A (es) Utilizacion de albumina humana terapeutica para la preparacion de un medicamento para el tratamiento de pacientes afectados por desordenes cognitivos.
DE60111025D1 (de) Verwendung von Topiramat zur Behandlung und Diagnostizierung von Atemstörungen während des Schlafens und Mittel zur Durchführung der Behandlung und Diagnose
NO20006506L (no) Anvendelse av valproinsyreanalog for behandlingen og forebyggelsen av migrene og affektive sykdommer
WO2003057162A3 (en) Combination for the treatment of immunoinflammatory disorders and proliferative skin diseases
WO2005046605A3 (en) Compositions and methods of treating neurological diseases
TW200501934A (en) Therapeutic causing contraction of mucosal tissue, method of treating diseases relating to mucosal tissues, injector and therapeutic set
RU2531693C1 (ru) Способ лечения церебрального ишемического инсульта в остром периоде
RU2329835C1 (ru) Способ лечения миофасциального болевого дисфункционального синдрома лица с использованием динамической электронейростимуляции
MX2023003258A (es) Tratamiento de enfermedades mediadas por nf-kb.
EA200702534A1 (ru) Применение бензоильного производного 3-аминокарбазола для лечения расстройства, связанного с продукцией простагландина e2(pge2)
RU2759471C1 (ru) Способ лечения посттравматических парезов и невритов лицевого и тройничного нервов у онкологических больных опухолями головы и шеи в раннем послеоперационном периоде на этапах комбинированного лечения
RU2486927C1 (ru) Способ лечения остеоартроза височно-нижнечелюстного сустава
RU2300401C1 (ru) Способ реабилитации больных с переломами длинных костей
MA26796A1 (fr) Derive d'aminotetraline pour la therapie des maladies cardiovasculaires.
Aaron Womack et al. Dry needling as a novel intervention for cervicogenic somatosensory tinnitus: a case study